Changing What’s Possible in Equine & Animal Care Through advanced photonic technology designed to support health and vitality
Click here to be a part of the #RU4It Campaign!What is it? – Photonic Corpuscular Irradiation (PCI) is a light-based therapeutic technology performed through a clinically guided process involving a small blood draw. During treatment, blood is exposed to specific wavelengths of light and then returned to the body, where this interaction is intended to support natural physiological responses related to immune function, circulation, and cellular activity.
What can it do? The PCI Treatments inactivate and destroy any and all Pathogens (Bacterial, Viral, Fungal diseases) en Vivo without causing any adverse effects. This treatment has been shown to work where conventional veterinary treatments have failed with therapies such as Antibiotics.
Has it been tested? – The technology was originally evaluated in human clinical settings, including investigational applications related to HIV/AIDS and leishmaniasis, and has since been applied in veterinary environments—most notably in horses. PCI may be used independently, with treatment decisions guided by veterinary expertise, and ongoing evaluation supports future application across additional animal populations, including beef cattle, dairy cows (both conventional and organically raised), pigs, sheep, goats, and companion animals such as dogs and cats. All applications are performed under veterinary direction and tailored to the individual animal.
Bacterial Diseases GONE
Fungal Diseases GONE
Viral Diseases GONE
Other Diseases GONE
Our Story
Where It All Began
Breakthrough Discovery in the Treatment of The Corona Virus, HIV/AIDS, and other Catastrophic Diseases.
Thirty years ago, Dr. Danilo Fernandez discovered an innovative way of treating all types of viral, bacterial, fungal, and parasitic diseases that afflict both humans and animals.
In 2000 he designed a Blood Irradiation machine that treats the blood in such a way that it eliminates all pathogens from the bloodstream without any morphological changes or damage to the blood
Introducing
Photonic Corpuscular Irradiation (PCI-1)
PCI excites the molecules of the blood, which is then re-introduced to the body and as it circulates throughout the bloodstream, it destroys viruses, bacteria, fungi, and parasites. No pathagenic resistence is seen with PCI, as is seen with Antibiotic resistance. In the case of Organically raised animals this eliminates the issues of not being able to sell the animals as “Organic” when treated with antibiotics.
GlobalMed Technologies (GMTUSA) has developed this unique, patented, world-changing biomedical process that works in both humans & animals.
Update
Current Situation
The Situation
Globally there have been over 79 million reported cases of COVID19 with more than 1.7 million deaths since the start of the pandemic. (WHO)
Urgency
The world is at an unprecedented impasse collecting scientific data as rapidly as possible to enable a treatment process that will stop the onslaught of COVID19 infections. Operation Warp Speed is in effect with the goal to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (countermeasures).
Vaccines
42% of U.S. adults say they would not get a vaccine and an unknown % of the overall population will have severe allergic reactions to the vaccines. Additionally, people with an allergy to PEG or polysorbate are being told not to get an mRNA COVID-19 vaccine. For this and other reasons, an alternative treatment to this life threatening virus is urgently needed.
Our Purpose
GlobalMed Technologies (GMT) is dedicated to making their PCI treatment readily available to people all over the world, from all walks of life, that are either refusing or allergic to antiretrovirals, We can increase the quality of these people’s lives with our treatment.
Current Clinical Trials
Over the next few days and weeks, GMT will sponsor several phased clinical trials including adults with confirmed COVID19 in the US.
Where we’ve been
History of GlobalMed
In 2003, Dr. Danilo Fernandez received a U.S. patent for his product and process. In 2004 a government-approved, Phase I Controlled Clinical Trial was conducted on 36 Human patients with acute and chronic HIV/AIDS. These patients’ viral loads were reduced by 85 to 99% and their CD4-cells (T-helper cells) were stabilized and reduced. Most importantly, 100% of opportunistic infections (OIs) were eliminated and none of these patients were given anti-viral medications, either prior to or during the trial. Between 2006 and 2009, GMT completed an additional pilot study on 7 patients, in order to prove and repeat the results achieved in Phase I. GMT not only surpassed earlier results but also showed that the 7 Chronic HIV patients (who had been hospitalized between 5 to 7 times a year in the past) did not require hospitalization or any anti-retroviral medications, for the duration of the 29-month study.